10 things I hate about proteomics
Abstract
Despite the title, says Dr. Williams, “this presentation is about my romance with proteomics.” From myths about assay size (and why it’s annoying when people say, “3,000 proteins is enough”) to the issue surrounding cis pQTLs (and why they’re “a nice party trick, but mostly biologically boring”), Dr. Williams explains in a fun – but serious – way how proteomics is revolutionizing drug discovery research and precision medicine worldwide today. He also couldn’t resist telling the story about what happens when two proteins walk into a bar. (Spoiler alert: This is why he has a career in medicine and not in stand-up comedy.)
Stephen A. Williams, MD, PhD
Chief Medical Officer
SomaLogic, Inc.
Stephen Williams, MD, PhD, is Chief Medical Officer at SomaLogic and is responsible for Clinical R&D, Medical Affairs, and Regulatory and Quality. He oversees clinical application of the SomaScan® Platform and has also had roles in launching the life sciences commercial business, assay development and bioinformatics.
Read more about Dr. Williams here.
10 things I hate about proteomics
A presentation by Stephen Williams, MD, PhD
More webinars
WebinarCorrelation of a Nonalcoholic Steatohepatitis Proteomic Test with Clinical Outcomes
In this webinar, Anne Minnich, PhD, biomarker consultant at Bristol Myers Squibb, presents research on the use of the new SomaSignal(TM) NASH bundle test in a recently completed clinical trial.
WebinarHarnessing AI and proteomics for glioblastoma
The development and advancement of aptamer technology opens vast possibilities for unlocking the biocomplexity available within proteomics. Learn more about the powerful tools that are enabling the discovery and validation of clinically relevant biomarkers and accelerating research.
WebinarMapping the human mucosal immune response to respiratory viruses
Conventionally, human immune responses have been extensively characterized using blood. Immune cells, though abundant in blood, are also found in various tissues in varying numbers and with locally relevant functional specification. Assessing immune responses in the airways over the course of infection and convalescence is critical to comprehensively mapping immunity to respiratory viral infections including influenza and SARS-CoV-2.